Answers are grounded in this paper and cite their sources.
To compare infusion-related costs for hypothetical US adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) receiving maintenance therapy with HyQvia (Immune Globulin [Ig] Infusion 10% [Human] with Recombinant Human Hyaluronidase; fSCIG-10%) versus Hizentra (Ig Subcutaneous [Human], 20% Liquid; SCIG-20%).
No takes yet. Share an insight, caveat, or question.
Khandelwal et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: